Burning Rock Biotech Ltd
NASDAQ:BNR
Relative Value
The Relative Value of one BNR stock under the Base Case scenario is 4.7558 USD. Compared to the current market price of 0.7864 USD, Burning Rock Biotech Ltd is Undervalued by 83%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
BNR Competitors Multiples
Burning Rock Biotech Ltd Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
CN |
Burning Rock Biotech Ltd
NASDAQ:BNR
|
80.7m USD | 1.1 | -0.9 | 0 | 0 | ||
US |
Abbvie Inc
NYSE:ABBV
|
286.7B USD | 5.3 | 59.5 | 12.9 | 19.7 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
144.8B USD | 5.1 | 21.6 | 16.1 | 24.1 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.5B USD | 10.4 | 28.3 | 22.6 | 23.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
96.9B USD | 7.4 | 24.5 | 16.2 | 17.8 | ||
AU |
CSL Ltd
ASX:CSL
|
132B AUD | 6.1 | 34.9 | 21.2 | 26.2 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.6B USD | 3 | 14.4 | 7.9 | 10.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
41.2B USD | 6 | -8.7 | -9.2 | -7.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
29.9B USD | 3 | 25.8 | 14 | 17.4 | ||
KR |
Celltrion Inc
KRX:068270
|
36.6T KRW | 16.8 | 68.3 | 41.9 | 57.7 |